Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Int J Gynaecol Obstet ; 45(3): 269-73, 1994 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-7926247

RESUMEN

OBJECTIVES: To evaluate the use of a double balloon catheter in the termination of pregnancy with fetal death in the second and third trimesters, in comparison with the administration of extra-amniotic PGF2-alpha. METHODS: Twenty cases with IUFD at > 20 weeks of gestation were divided into two groups. Group I was subjected to the double balloon alone, while in Group II extra-amniotic instillation of PGF2-alpha via a Foley's catheter was used. RESULTS: There were no significant differences between the two groups with regard to induction-expulsion time, induction-delivery time and failure rate. CONCLUSIONS: The double balloon catheter proved to be an effective non-pharmacological method. The technique was simple and well tolerated by the patients. The side-effects of the prostaglandin and the cost of the medication were avoided.


Asunto(s)
Aborto Inducido/métodos , Cateterismo , Dinoprost/uso terapéutico , Muerte Fetal , Adulto , Femenino , Humanos , Embarazo , Segundo Trimestre del Embarazo , Tercer Trimestre del Embarazo
2.
Int J Gynaecol Obstet ; 29(4): 325-8, 1989 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-2571534

RESUMEN

Induction of labor was performed in 20 pregnant females with postmaturity (greater than 294 days) using either oral PGE2 tablets (0.5 mg) or i.v. oxytocin drip (each group n = 10). The induction-establishment interval was significantly shorter in the oxytocin group (P less than 0.005). Moreover, the uterine activity (in Alexandria units) at 3 h post-induction and at the end of the first stage of labor, was significantly higher with i.v. oxytocin (P less than 0.005). However, the induction-delivery interval did not differ in both groups. All cases delivered spontaneously with a satisfactory Apgar score.


Asunto(s)
Dinoprostona/administración & dosificación , Trabajo de Parto Inducido/métodos , Embarazo Prolongado/efectos de los fármacos , Administración Oral , Adulto , Dinoprostona/efectos adversos , Femenino , Monitoreo Fetal , Frecuencia Cardíaca Fetal/efectos de los fármacos , Humanos , Infusiones Intravenosas , Oxitocina/administración & dosificación , Oxitocina/efectos adversos , Embarazo , Contracción Uterina/efectos de los fármacos
4.
Clin Exp Hypertens B ; 2(2): 217-32, 1983.
Artículo en Inglés | MEDLINE | ID: mdl-6872285

RESUMEN

Pilot studies showed that, i.v. infusions of the renal prostaglandin A1 (PGA1) induced a triad of beneficial clinical responses in severe pre-eclampsia; the blood pressure became normotensive, renal function was markedly improved and labour was successfully induced. The present study was an attempt to develop a therapeutic schedule of PGA1 administration in severe toxemia. Twenty one cases of severe pre-eclampsia (in 3 equal groups) received i.v. infusions of PGA1 in a dose range of 0.1-0.5 microgram/kgm/min for 12 - 24 hours and the B.P., uterine activity and FHR were continuously monitored during and for 12 hours following the infusion period. The 0.1 microgram/Kgm/min dose for 12 hours was inadequate while 0.5 microgram/Kgm/min for 12 hours induced a good hypotensive response and the cases delivered within 48 hours but a post-infusion rebound in hypertension was observed. The dose of 0.5 microgram/Kgm/min for 24 hours appeared to be optimal in clinical terms since a satisfactory effect on B.P. was recorded and all the subjects delivered normal babies during the infusion period with minimal or no post-infusion rebound rise in B.P. This approach holds a major potential in the treatment of severe pre-eclampsia.


Asunto(s)
Preeclampsia/tratamiento farmacológico , Mantenimiento del Embarazo/efectos de los fármacos , Prostaglandinas A/administración & dosificación , Adolescente , Adulto , Presión Sanguínea/efectos de los fármacos , Femenino , Corazón Fetal/fisiología , Frecuencia Cardíaca/efectos de los fármacos , Humanos , Recién Nacido , Infusiones Parenterales , Embarazo , Prostaglandinas A/efectos adversos , Proteinuria/complicaciones , Factores de Tiempo , Contracción Uterina/efectos de los fármacos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA